Aura Biosciences Correlations
AURA Stock | USD 8.73 0.16 1.80% |
The current 90-days correlation between Aura Biosciences and Acrivon Therapeutics, Common is 0.39 (i.e., Weak diversification). The correlation of Aura Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Aura Biosciences Correlation With Market
Weak diversification
The correlation between Aura Biosciences and DJI is 0.37 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aura Biosciences and DJI in the same portfolio, assuming nothing else is changed.
Aura |
Moving together with Aura Stock
0.76 | MBIO | Mustang Bio | PairCorr |
0.65 | RANI | Rani Therapeutics | PairCorr |
0.82 | ABOS | Acumen Pharmaceuticals | PairCorr |
0.62 | AQST | Aquestive Therapeutics | PairCorr |
0.63 | AVDL | Avadel Pharmaceuticals | PairCorr |
Moving against Aura Stock
0.45 | DYAI | Dyadic International | PairCorr |
0.46 | BNTX | BioNTech SE Downward Rally | PairCorr |
0.37 | TELO | Telomir Pharmaceuticals, | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Aura Stock performing well and Aura Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aura Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
AVTE | 2.38 | 0.44 | 0.17 | 0.63 | 1.99 | 5.58 | 19.11 | |||
ADAG | 4.73 | (0.35) | 0.00 | (1.28) | 0.00 | 8.13 | 41.45 | |||
ACRV | 2.62 | (0.41) | 0.00 | (0.21) | 0.00 | 4.83 | 19.02 | |||
RZLT | 2.57 | (0.25) | 0.00 | (0.28) | 0.00 | 5.54 | 16.12 | |||
ANTX | 2.50 | 0.52 | 0.17 | 0.87 | 2.03 | 6.34 | 28.89 | |||
SEER | 2.15 | 0.55 | 0.23 | 0.78 | 1.74 | 6.32 | 15.38 | |||
ORIC | 2.82 | (0.39) | 0.00 | (0.10) | 0.00 | 5.15 | 20.53 | |||
ANEB | 4.69 | (0.21) | 0.00 | 0.32 | 0.00 | 7.64 | 76.00 | |||
CGEM | 2.87 | (0.73) | 0.00 | (0.29) | 0.00 | 5.88 | 17.85 | |||
CCCC | 3.65 | (0.55) | 0.00 | (0.68) | 0.00 | 9.28 | 23.66 |
Aura Biosciences Corporate Management
Richard Mountfield | Senior Quality | Profile | |
Patrick Nealon | Senior Operations | Profile | |
CPE MBA | Chief RD | Profile | |
Jill MD | Chief Development | Profile | |
Amy Elazzouzi | Interim Officer | Profile | |
Paulo Carvalho | VP Operations | Profile | |
Bruce MD | Senior Oncology | Profile |